Trinity Biotech (Trinity Biotech) Total Current Assets : $43.83 Mil (As of Sep. 2023)

View and export this data going back to 1995. Start your Free Trial

What is Trinity Biotech Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Trinity Biotech's total current assets for the quarter that ended in Sep. 2023 was $43.83 Mil.

Trinity Biotech Total Current Assets Historical Data

The historical data trend for Trinity Biotech's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Trinity Biotech Total Current Assets Chart

Trinity Biotech Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Current Assets

Get a 7-Day Free Trial

86.66

71.39

83.30

72.69

46.67

Trinity Biotech Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Total Current Assets	Get a 7-Day Free Trial															49.83	46.67	58.26	52.92	43.83

Trinity Biotech Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Trinity Biotech's Total Current Assets for the fiscal year that ended in Dec. 2022 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	6.578	+	15.655	+	22.503	+	1.932
	=	46.67

Trinity Biotech's Total Current Assets for the quarter that ended in Sep. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	6.261	+	16.687	+	20.88	+	0
	=	43.83

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Trinity Biotech (NAS:TRIB) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Trinity Biotech's Liquidation Value for the quarter that ended in Sep. 2023 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	6.261	-	81.084	+	0.75 * 15.095	+	0.5 * 20.88
=	-53.06

Trinity Biotech Total Current Assets Related Terms

Thank you for viewing the detailed overview of Trinity Biotech's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Trinity Biotech (Trinity Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Trinity Biotech PLC (NAS:TRIB) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

TRBA:Germany

Address

IDA Business Park, Bray, County Wicklow, Dublin, IRL, A98 H5C8

Website

https://www.trinitybiotech.com

Trinity Biotech PLC is in the business of development, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point of care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Premier, Immublot, EZ, Capita, and others. Geographically, it has two segments namely the Americas, and Rest of World - Ireland of which it derives a majority of its revenues from the Americas segment.